Clinical trials for AL amyloidosis
57 recruiting or active trials synced from ClinicalTrials.gov.
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data- RECRUITINGPhase 3NCT06963216A Study Investigating Coagadex in the Treatment AFXD Associated With AL AmyloidosisKedrion S.p.A. · PI: Mirella Calcinai, MD
- RECRUITINGPhase 3NCT07388602A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis (NDSLCA)Sinocelltech Ltd.
- RECRUITINGPHASE1, PHASE2NCT07266116Assessment of the Efficacy and Safety of Injectable TQB2934 (Subcutaneous Injection) in Systemic Light Chain Amyloidosis PatientsShanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
- RECRUITINGNCT07448935One Gene, Two Diseases: the Pathologic Role of IGLV1-44 in AL Amyloidosis and POEMSFondazione IRCCS Policlinico San Matteo di Pavia
- RECRUITINGNCT07448779Investigating the Pathogenic Role of N-glycosylation in AL Amyloidosis: Molecular Bases, Diagnosis, and TreatmentFondazione IRCCS Policlinico San Matteo di Pavia
- RECRUITINGPhase 2NCT07110844Teclistamab-Daratumumab in AL AmyloidosisSuzanne Lentzsch, MD · PI: Suzanne Lentzsch, MD, PhD
- RECRUITINGPhase 1NCT07250269Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL AmyloidosisGracell Biotechnologies (Shanghai) Co., Ltd.
- RECRUITINGNCT07172243BE.Amycon Biobank & Data Registry UZ LeuvenUniversitaire Ziekenhuizen KU Leuven · PI: Michel Delforge
- RECRUITINGPhase 2NCT07151690BCMA/CD3 Bispecific Antibody Treatment for Newly Diagnosed AmyloidosisInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE1, PHASE2NCT07081646A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.Alexion Pharmaceuticals, Inc.
- RECRUITINGPhase 2NCT07039578Study Evaluating the Efficacy and Safety of CM336 Injection in the Treatment of Light-Chain AmyloidosisKeymed Biosciences Co.Ltd · PI: Jian Li
- RECRUITINGNCT07232459[18F]FT8 PET Imaging in Immunoglobulin Light Chain AmyloidosisTianjin Medical University
- RECRUITINGPhase 2NCT06649695A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) AmyloidosisEuropean Myeloma Network B.V. · PI: Murielle Roussel, MD
- RECRUITINGPhase 2NCT07079423Teclistamab in Newly Diagnosed Mayo Stage IIIB AL AmyloidosisPeking Union Medical College Hospital
- RECRUITINGEarly Phase 1NCT07085559Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms Clinical ResearchAnhui Provincial Hospital
- RECRUITINGPhase 2NCT06935162Teclistamab in Previously Treated AL AmyloidosisPeking Union Medical College Hospital
- RECRUITINGN/ANCT06699394Prospective Study of Teclistamab in the Treatment of Systemic AL AmyloidosisPeking University People's Hospital · PI: Jin Lu, M.D.
- RECRUITINGPhase 2NCT06971380Study of HBI0101 (NXC-201) CAR-T Therapy in Multiple Myeloma and Light-Chain AmyloidosisPolina Stepensky
- RECRUITINGN/ANCT06983951Exploratory Clinical Study on the Safety and Efficacy of Targeted BCMA Autologous CART Cell Injection in Subjects With Recurrent/Refractory Light Chain AmyloidosisBeijing Boren Hospital · PI: yajing zhang, MD/PhD
- ENROLLING BY INVITATIONN/ANCT07103863Multimodal Radiomics Model (18F-FAPI PET/CT + CMR) for AL Cardiac Amyloidosis PrognosisBeijing Anzhen Hospital · PI: wei dong, MD,PHD
- RECRUITINGNCT06855121The Norwegian Immunotherapy in Multiple Myeloma StudySt. Olavs Hospital
- RECRUITINGPHASE1, PHASE2NCT06569147Elranatamab in Patients With Relapsed or Refractory AL AmyloidosisBrigham and Women's Hospital · PI: Giada Bianchi
- RECRUITINGPhase 2NCT06629818Daratumumab Combined With Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis With Translocation (11;14)Peking Union Medical College Hospital
- RECRUITINGPHASE1, PHASE2NCT06292780A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)Regeneron Pharmaceuticals · PI: Clinical Trial Management
- RECRUITINGPhase 2NCT06420167DapagliFLOzin in Renal AL Amyloidosis (FLORAL)Barbara Ann Karmanos Cancer Institute · PI: Jeffrey Zonder, M.D.
- RECRUITINGPhase 3NCT06022939Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL AmyloidosisSWOG Cancer Research Network · PI: Patrick A Hagen
- RECRUITINGPHASE1, PHASE2NCT06097832Study of NXC-201 CAR-T in Patients With Light Chain (AL) AmyloidosisNexcella Inc.
- RECRUITINGPhase 2NCT06342466Bortezomib, Pomalidomide, Dexamethasone for Systemic AL AmyloidosisJin Lu, MD · PI: Jin Lu
- RECRUITINGNCT06365060Screening for AL Amyloidosis in Smoldering Multiple MyelomaTufts Medical Center
- RECRUITINGPHASE1, PHASE2NCT06158854A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) InfusionAbbVie · PI: ABBVIE INC.
- RECRUITINGN/ANCT06455748Daratumumab/Daratumumab and Hyaluronidase-fihj in Combination With Pomalidomide and Dexamethasone for the Treatment of Patients With Newly Diagnosed AL Amyloidosis: a Prospective, Multicenter, Single-arm StudyYongyong MA · PI: Yongyong Ma, MD
- RECRUITINGPHASE1, PHASE2NCT05145816Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL AmyloidosisUniversity of Texas Southwestern Medical Center · PI: Larry Anderson, MD
- RECRUITINGN/ANCT06192979Optimize First-line Treatment for AL Amyloidosis With t (11; 14)Jin Lu, MD · PI: Jin Lu
- RECRUITINGNCT06205953A EUropean REgistry and Sample Sharing networK to Promote the Diagnosis and Management of Light Chain Amyloidosis (EUREKA)Fondazione IRCCS Policlinico San Matteo di Pavia
- ACTIVE NOT RECRUITINGPhase 2NCT05996406Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis with Translocation (11;14)Peking Union Medical College Hospital
- RECRUITINGPhase 1NCT05978661FKC288 for Relapsed or Refractory Systemic Light Chain (AL) AmyloidosisNanjing University School of Medicine · PI: Xianghua Huang, MD
- RECRUITINGPhase 2NCT05898646Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA TrialMayo Clinic · PI: Taxiarchis Kourelis, MD
- RECRUITINGNCT06383143Promoting Diagnosis and Management of AL in Italy (ProDigALIty)Fondazione IRCCS Policlinico San Matteo di Pavia
- RECRUITINGPhase 3NCT05184088Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL AmyloidosisLife Molecular Imaging GmbH · PI: Andrew Stephens, MD, PhD
- RECRUITINGN/ANCT06376214Daratumumab for Patients With Light Chain AmyloidosisNanjing University School of Medicine · PI: Xianghua Huang, MD
- RECRUITINGPhase 1NCT05652335A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) AmyloidosisJanssen Research & Development, LLC · PI: Janssen Research & Development, LLC Clinical Trial
- RECRUITINGPHASE1, PHASE2NCT05451771Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) AmyloidosisRajshekhar Chakraborty, MD · PI: Rajshekhar Chakraborty, MD
- RECRUITINGPhase 1NCT04847453Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain AmyloidosisNational Cancer Institute (NCI) · PI: Michael A Rosenzweig
- ACTIVE NOT RECRUITINGPhase 2NCT05250973A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) AmyloidosisJanssen Research & Development, LLC · PI: Janssen Research & Development, LLC Clinical Trial
- RECRUITINGNCT05283993A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFHPeking University First Hospital
- ACTIVE NOT RECRUITINGPhase 1NCT04754945Isatuximab as Upfront Therapy for the Treatment of High Risk AL AmyloidosisEmory University · PI: Craig C Hofmeister, MD, MPH
- ACTIVE NOT RECRUITINGPhase 2NCT04270175Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to DaratumumabWeill Medical College of Cornell University · PI: mateo Mejia Saldarriaga, MD
- ACTIVE NOT RECRUITINGPhase 3NCT04512235A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)Alexion Pharmaceuticals, Inc. · PI: Scott Swenson, MD
- ACTIVE NOT RECRUITINGPhase 3NCT04504825A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)Alexion Pharmaceuticals, Inc. · PI: Scott Swenson, MD
- RECRUITINGNCT04839003A Registry of AL Amyloidosis (ReAL)Fondazione IRCCS Policlinico San Matteo di Pavia
- ACTIVE NOT RECRUITINGPhase 2NCT03618537Ixazomib Maintenance Study in Patients With AL AmyloidosisMemorial Sloan Kettering Cancer Center · PI: Heather Landau, MD
- RECRUITINGNCT03717844Registry for Adults With Plasma Cell Disorders (PCD's)UNC Lineberger Comprehensive Cancer Center · PI: Sascha Tuchman, MD
- ACTIVE NOT RECRUITINGPhase 1NCT03283917Daratumumab, Ixazomib, and Dexamethasone in AL AmyloidosisM.D. Anderson Cancer Center · PI: Oren Pasvolsky
- ACTIVE NOT RECRUITINGPhase 2NCT03315026Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL AmyloidosisMemorial Sloan Kettering Cancer Center · PI: Gunjan Shah
- ACTIVE NOT RECRUITINGPhase 1NCT02909036Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant.Memorial Sloan Kettering Cancer Center · PI: Heather Landau, MD
- RECRUITINGNCT01408225Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample ResourceOhio State University Comprehensive Cancer Center · PI: Don Benson, MD
- ENROLLING BY INVITATIONNCT04210791Autologous Stem Cell Transplantation for Patients With AL AmyloidosisNanjing University School of Medicine · PI: Zhihong Liu, MD